Rethinking brain health

We are on a mission to change the way the world thinks about brain health.

Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative conditions.

The Challenge

Our novel technology assesses brain health based on changes in the cellular structure.

Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative conditions.

This gives us the potential to revolutionise how people think about brain health.

Our solution

Supporting more efficient drug development and personalised patient care.

Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.

Our Science

Our products


  • Measures you can trust
  • Get more from your MRI
  • Run targeted, more efficient clinical trials
  • Efficient use of technology across multiple conditions

Our products


  • Supporting patient care
  • Helping clinicans in their diagnosis
  • Differential patterns of brain changes
  • Accurately tracking changes
  • Proactive brain health

Clinical Information

Latest news

Our collaboration with Sinaptica Therapeutics goes from strength to strength.
News Release
10 July 2024

Study by Sinaptica scientific co-founders published in Alzheimer's Research & Therapy. Imaging analysis revealed personalized rTMS-EEG preserved structural integrity, enhanced functional connectivity, and slowed atrophy in areas of the Default Mode Network, the primary memory network impacted by Alzheimer’s that is targeted by the therapy. In addition to preserving grey matter at the macro level, detailed microimaging analysis, supported by an independent company , Oxford Brain Diagnostics Ltd, also showed that the neuromodulation treatment preserved microstructural integrity of the Precuneus, as measured by AngleR, a proprietary measure of microcortical damage, as well as across regions of the DMN, with high spatial specificity.

SimonMed Announces Research Collaboration with Oxford Brain Diagnostics
News Release
20 June 2024

SimonMed Announces Research Collaboration with Oxford Brain Diagnostics to Leverage Cortical Disarray Measurement (CDM®) in Diagnosing Neurodegenerative Diseases. SCOTTSDALE, Ariz., June. __, 2024 – SimonMed Imaging ("SimonMed"), one of the largest outpatient medical imaging providers and radiology practices in the United States, announces today its research collaboration with Oxford Brain Diagnostics to explore using Cortical Disarray Measurement (CDM) to better diagnose neurodegenerative diseases.

OBD Guest Speaker series - Dr Clifford Jack
31 August 2023

Dr Clifford Jack provides an invaluable reminder to us all on the history of how the NIA-AA framework came into existence, the evolution of the ATN framework and openly talks around the controversial viewpoints for the disease condition. With the upcoming draft review of the NIA-AA Clinical Criteria for Alzheimer’s Disease (AD), it is timely for us all to reflect upon how complex Alzheimer's disease actually is. We look forward to seeing the final version of the updated NIA-AA guideline document soon.

ISO 13485:2016 Approved
News Release
30 August 2023

We are pleased to annouce that OBD has been awarded the ISO 13485:2016 Quality standard. Quality of work, standards, processes and people will ensure we reach our goals in supporting clinicians, patients and their families in defeating Alzheimer's disease and other neurodegenerative diseases. Accredited scope of goods or services in respect of which the business is registered: Cortical Disarray Measurement (CDM) software developed to produce measurements of microstructure in the brain, to support a trained medical practitioner to make a diagnosis of Alzheimer’s disease or other neurodegenerative brain conditions.